| ATC Code | M01AH05 |
| CAS number | 202409-33-4 |
| PUB number | 123619 |
| Drugbank ID | DB01628 |
| Empirical formula | C18H15ClN2O2S |
| Molar mass (g·mol−1) | 358,84 |
| Physical state | solid |
Etoricoxib is a new COX-2 selective inhibitor and belongs to the group of so-called NSAIDs (Non Steroidal Anti Inflammatory Drugs). Indications are: Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain, and gout. Etoricoxib is available by prescription only.
Etoricoxib is a new COX-2 selective inhibitor. The enzyme cyclooxygenase is significantly involved in inflammatory processes and in the development of pain. Etoricoxib selectively inhibits the isoenzyme COX-2.
Bioavailability is 100% after oral administration. Plasma protein binding is approximately 92 %. Elimination is hepatic, mainly via the enzyme CYP3A4. The half-life is about 22 hours.
Possible adverse effects:
In addition, there is an increased risk of thromboembolic events with the use of coxiben due to selective inhibition of COX-2. Therefore, use is contraindicated in cardiovascular risk patients.
Markus Falkenstätter, BSc
Mag. pharm. Stefanie Lehenauer
Browse our extensive database of medications from A-Z, including effects, side effects, and dosage.
All active ingredients with their effects, applications, and side effects, as well as the medications they are contained in.
Symptoms, causes, and treatments for common diseases and injuries.
The presented content does not replace the original package insert of the medication, especially regarding the dosage and effects of individual products. We cannot assume liability for the accuracy of the data, as the data has been partially converted automatically. Always consult a doctor for diagnoses and other health-related questions.
© medikamio